CJC-1295 ohne DAC

CJC-1295 No DAC - Short-Acting GHRH Analog

CJC-1295 No DAC (also known as Mod GRF 1-29, or Modified Growth Hormone Releasing Factor 1-29) is a synthetic analog of the first 29 amino acids of native GHRH - the endogenous hormone that tells the pituitary to release growth hormone. The peptide has been structurally modified at four positions to resist enzymatic breakdown, but unlike the “DAC” version it has no albumin-binding adapter, which keeps its half-life short (about 30 minutes) and preserves the natural pulsatile GH release pattern researchers want to characterize.

Why Mod GRF 1-29 Matters

Native GHRH(1-29) is the active portion of the full 44-amino-acid hormone but is degraded within minutes by the enzyme DPP-4. CJC-1295 No DAC carries four amino-acid substitutions that block this breakdown and roughly 10x the circulating half-life while keeping the short-pulse pharmacokinetics intact. That makes it useful for studies where researchers want to stimulate GH release without flattening it into a sustained plateau.

CJC-1295 No DAC vs CJC-1295 with DAC

The only mechanistic difference is the DAC (Drug Affinity Complex) adapter, but it completely changes how the peptide behaves over time.

Forschungsanwendungen

CJC-1295 No DAC is used in studies examining:

• Charakterisierung der pulsatilen GH-Freisetzung
• GHRH + GHRP combination research (typically paired with Ipamorelin)
• IGF-1 dose-response curves
• Endpunkte zur Körperzusammensetzung und Regeneration unter Stimulation der GH-Achse
• Comparative pharmacokinetics vs. DAC and vs. sermorelin

Technische Daten

Storage & Handling

Unopened vials are kept at 2-8°C under standard cold-chain conditions and remain stable for 12+ months. Reconstitution parameters, solvent compatibility, and post-reconstitution stability for CJC-1295 No DAC are documented in the published peer-reviewed literature and standard peptide-chemistry references.

Reference Literature

Published clinical and preclinical CJC-1295 No DAC literature is available through PubMed, Google Scholar, and other peer-reviewed databases. WWP does not provide protocol design, dosing guidance, or administration parameters. Those decisions rest with the researcher and any applicable institutional review board.

Common Questions About CJC-1295 No DAC

Is it better to use CJC-1295 with DAC or without?

They are used for different study designs. DAC produces a sustained, non-pulsatile GH elevation (half-life ~1 week). No DAC preserves the natural pulsatile pattern (half-life ~30 min). For pulse-characterization studies paired with a GHRP like Ipamorelin, No DAC is the standard. For long-duration sustained-IGF-1 studies, DAC is used.

What does CJC No DAC do in research?

It activates the pituitary GHRH receptor, triggering a short pulse of GH release. Downstream, that GH converts to IGF-1 in the liver. Most published studies track IGF-1 levels as the primary biomarker.

How often is CJC-1295 No DAC administered in published protocols?

Published protocols most commonly report 1-3 administrations per day, with at least one pre-sleep administration to align with the body’s own nocturnal GH pulse. The short half-life is why it’s multi-dose rather than weekly like the DAC version.

Is CJC-1295 No DAC FDA approved?

No. CJC-1295 is not FDA approved for any human use. Every vial WWP ships is labeled and sold strictly for laboratory and research use only.

How is CJC-1295 No DAC stored?

Ungeöffnete Fläschchen werden bei 2–8 °C gelagert und sind mindestens 12 Monate haltbar. Nach der Rekonstitution mit bakteriostatischem Wasser wird die Lösung bei 2–8 °C aufbewahrt und innerhalb von 28–30 Tagen verbraucht.

Reinheitsgarantie

Jede Charge weist eine Reinheit von ≥99 % auf. Senden Sie uns ein Analysezertifikat einer unabhängigen Prüfstelle, und wir stellen Ihnen unabhängig vom Ergebnis eine Gutschrift aus.